Gelesis Unveils Novel Non-Invasive Capsulated Device for Obesity and Presents Clinical Data; Appoints Former Pfizer R&D President to Board

BOSTON, April 22 (HSMN NewsFeed) -- Boston-based medical technology firm Gelesis, Inc. unveiled its capsulated device Attiva™, and presented data showing that Attiva™ significantly increased the post-meal feeling of satiety and reduced hunger between meals in obese patients. This data was presented today at the American Association of Clinical Endocrinologists (AACE) 19th Annual Meeting & Clinical Congress

Attiva™, the first and only superabsorbent hydrogel composed entirely from food components, is administered in the form of small particles that are designed to swell after ingestion with water and occupy the gastric and intestinal cavities, inducing a feeling of satiety that lasts beyond its transit time in the stomach. Afterwards, it safely degrades in the colon and releases absorbed liquids. When fully swollen, the product creates very small and individual gel beads that are mixed homogenously with the food in the stomach and also have the same elasticity and viscosity as foods.

Full text >>